Ocular Therapeutix™ To Report First Quarter 2023 Financial Results

Rhea-AI Summary

Ocular Therapeutix, Inc. (NASDAQ:OCUL) will report its financial results for the first quarter ending March 31, 2023, on May 8, 2023. Following the earnings release, a live conference call is scheduled for 4:30 PM Eastern Time to discuss the results and provide a business update. Ocular Therapeutix specializes in innovative therapies for eye conditions, with its first commercial product, DEXTENZA®, FDA-approved for treating ocular inflammation and associated pain. The company is also advancing several clinical trials, including OTX-TKI for wet AMD, OTX-TIC for glaucoma, and treatments for dry eye disease.

Positive

• Successful launch and FDA approval of DEXTENZA®.
• Progress in multiple clinical trials for treatments targeting important eye conditions.

Negative

• None.

BEDFORD, Mass., April 24, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report first quarter ended March 31, 2023 financial results after the close on Monday, May 8, 2023. Following distribution of the earnings release via wire services, the Ocular Therapeutix management team will host a live conference call and webcast at 4:30 p.m. Eastern Time to review the Company’s financial results and provide a general business update.

Listeners can register for the webcast via this link. Those who plan on participating are advised to join 15 minutes prior to the start time. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the Company’s investor website approximately two hours after the call’s conclusion for 90 days.

About Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology. Ocular Therapeutix’s first commercial drug product, DEXTENZA®, is an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis. Ocular Therapeutix’s earlier stage development assets include: OTX-TKI (axitinib intravitreal implant), currently in Phase 1 clinical trials for the treatment of wet AMD and diabetic retinopathy; OTX-TIC (travoprost intracameral implant), currently in a Phase 2 clinical trial for the treatment of primary open-angle glaucoma or ocular hypertension; and OTX-DED (dexamethasone intracanalicular insert) for the short-term treatment of the signs and symptoms of dry eye disease; and OTX-CSI (cyclosporine intracanalicular insert) for the chronic treatment of dry eye disease, both of which have completed Phase 2 clinical trials.

Investors
Ocular Therapeutix
Donald Notman
Chief Financial Officer
dnotman@ocutx.com

or

ICR Westwicke
Chris Brinzey, 339-970-2843
Managing Director
chris.brinzey@westwicke.com

FAQ

When will Ocular Therapeutix report its Q1 2023 financial results?

Ocular Therapeutix will report its Q1 2023 financial results on May 8, 2023.

What time is the conference call to discuss Ocular Therapeutix's financial results?

The conference call is scheduled for 4:30 PM Eastern Time on May 8, 2023.

What products are currently under development by Ocular Therapeutix?

Ocular Therapeutix is developing OTX-TKI for wet AMD, OTX-TIC for glaucoma, and treatments for dry eye disease.

What is DEXTENZA® used for?

DEXTENZA® is an FDA-approved corticosteroid for treating ocular inflammation and pain following ophthalmic surgery.

How can I access the replay of Ocular Therapeutix's financial results conference call?

A replay of the conference call will be available on Ocular Therapeutix's investor website approximately two hours after the call's conclusion.